Quiet Therapeutics

Anticancer Therapeutics Using Nanoparticles and Biomarkers

Health Tech & Life Sciences
Non Active, Feb 2017
Series A Ness Ziona, Israel Founded 2010
Last updated 2026-06-18
Total raised
$18.5M
Last: 2015-04
Stage
Series A
Founded
2010
Headcount
6
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

Quiet Therapeutics is a cancer drug discovery and development company that is creating a new generation of cancer therapeutics utilizing its proprietary GAGomer technology to specifically target tumor cells. The GAGomer therapeutic nanoparticles have the ability to target certain types of cancers that express a biomarker. Once the nanoparticles target the specific cancer cells, they deliver a therapeutic payload that leads to the death of the cancer cells. This new class of cancer treatment enables the flexibility of delivering a medicine that can kill the cancer cells, block the production of proteins that promote the cancer, or even use the cancer cells own machinery to produce proteins that kill the cancer cells. Quiet Therapeutics develops a diverse set of DNA, RNA, and small molecule anticancer therapeutics.

Funding history · 3 rounds · $18.5M total

2013-11
Grant $1.0M
2013-01

Q&A

What is Quiet Therapeutics' primary focus?
Quiet Therapeutics is a cancer drug discovery and development company focused on creating new generations of cancer therapeutics using its proprietary GAGomer technology to specifically target tumor cells.
Where is Quiet Therapeutics headquartered?
Quiet Therapeutics is headquartered in Ness Ziona, Israel, with an additional office in Lexington, MA, United States.
What is the current status of Quiet Therapeutics?
Quiet Therapeutics is currently inactive, as of February 2017.
How many employees does Quiet Therapeutics have?
Quiet Therapeutics has an employee count in the 1-10 range.
What is Quiet Therapeutics' total funding to date?
Quiet Therapeutics has raised a total of $18,500,000 USD.
When was Quiet Therapeutics' last funding round?
Quiet Therapeutics' last funding round occurred in April 2015, raising $12,000,000 USD from investors including Jerusalem Global Ventures.
Which investors participated in Quiet Therapeutics' January 2013 funding round?
In January 2013, Quiet Therapeutics received $5,500,000 USD from investors including Pontifax.
What type of funding did Quiet Therapeutics receive in November 2013?
In November 2013, Quiet Therapeutics received a $1,000,000 USD grant from the European Union.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

Verified

Tags

oncologybiotechnologybiomarkerspharmaceuticalsmedical-technologiesnanotechnologytherapeuticsdrug-deliveryinflammatory-diseasespharma-companiestargeted-therapycancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2010-1
Employees (exact)6
OfficesLexington
Status reasonNon Active, Feb 2017